EP-1489: Kilovoltage intrafraction monitoring trial for gated prostate radiotherapy: initial dosimetric results  by Juneja, P. et al.
3rd ESTRO Forum 2015                                                                                                                                         S809 
 
and pulmonary dose. To prevent patient lifting, patients 
should not be pushed to perform too high amplitudes. There 
are no benefits regarding reproducibility, stability and PGW of 
changing gating method from EIG to DIBH if no visual 
guidance can be provided.  
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Purpose/Objective: For volumetric modulated arc therapy-
stereotactic body radiation therapy (VMAT-SBRT), in-
treatment four-dimensional cone-beam CT (4D CBCT) images 
are the most reliable tool for evaluating setup error and the 
intrafractional location of the moving target. We established 
and updated a novel verification system and quantitatively 
assessed the accuracy of our VMAT-SBRT delivery through the 
use of it. 
Materials and Methods: Five patients undergoing VMAT-SBRT 
at our hospital were included in this analysis. All patients had 
stage I non-small cell lung cancer or single lesion 
oligometastatic lung tumors. In the supine position, an 
abdominal compressor and the Elekta stereotactic body 
frame were used. The gross tumor volumes (GTVs) were 
contoured on all 10 phases of the 4D planning CT. GTVs were 
merged into the internal target volume (ITV). The planning 
target volume (PTV) was created by adding a 5 mm margin to 
the ITV in all directions. Fifty-five Gy in 4 fractions was 
prescribed to cover 95% of the PTV. Before each treatment, 
registration was manually performed using pre-treatment 4D 
CBCT with the Elekta XVI system, v4.5 or v5.0. During each 
fraction, in-treatment 4D CBCT images, subdivided into 10 
phases were obtained and exported to Pinnacle3. The 
respective tumor locations during beam delivery, as 
determined with the 4D CBCT, were merged to form the 
'actual ITV.' We could then evaluate discrepancies between 
the 'actual ITV' and the planning ITV. To assess the adequacy 
of the PTV margin, we also analyzed whether PTV covered 
the 'actual ITV' completely. 
 
 
 
Results: From the 5 patients, 200 4D CBCT image sets taken 
during VMAT-SBRT were successfully obtained and the 
intrafractional tumor motions during beam delivery were 
reasonably reproduced. Under suppressed respiration, the 
average amplitude of tumor motion was 4.2±3.0mm in the 
cranio-caudal direction. On average, the 'actual ITV' covered 
87.2±5.6% of the planning ITV. In addition, the respective 
PTV encompassed all tumor locations in all phases. 
Conclusions: By using in-treatment 4D CBCT, we proved the 
adequacy of our ITV-PTV margin setting for VMAT-SBRT when 
the registration for moving lung tumors was performed using 
pre-treatment 4D CBCT. This result also provides valuable 
information prior to starting adaptive SBRT for lung tumors.   
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Purpose/Objective: Internal intra-fraction motion during 
radiotherapy can result in sub-optimal treatment delivery 
and thus real-time adaptation strategies such as MLC tracking 
or gating are currently being investigated in the clinic. The 
goal of this study is to investigate the dosimetric effect of 
gated prostate cancer radiotherapy utilising kilovoltage 
intrafraction monitoring (KIM) in the first prospective clinical 
trial. In KIM, prostate position monitoring by kV flouroscopy is 
used to gate off the beam and re-position the patient if the 
prostate moves outside a predefine region. 
Materials and Methods: KIM is being evaluated for real-time 
target localisation in a 30-patient prostate radiotherapy trial. 
So far, one patient has completed the 40 fraction treatment, 
and another two patients are currently undergoing 
treatment. The dose delivered during each fraction with KIM 
was calculated using an isocenter shift dose reconstruction 
method. For the fractions where a gating event (with motion 
exceeding 3mm for 5 seconds) occurred, dose calculation was 
also performed for a simulated treatment scenario with no 
KIM gating correction. Dosimetric impact of KIM gating was 
evaluated through comparison of target and normal tissue 
dose volume statistics for the planned treatment delivery, 
delivery with KIM gating and delivery with no KIM correction 
(see Figure 1), for each of the gated fractions. 
Results: In this preliminary work, all fractions from the first 
patient’s treatment were studied. Four fractions (out of 40) 
had successful KIM gating corrections. Prostate motion (mean 
± standard deviation) with KIM corrections and simulated 
with no KIM corrections were 2.2±1.4 mm and 4.1±0.7 mm 
respectively. Ranges of differences between the planned and 
KIM corrected doses and the planned and no KIM correction 
doses were respectively: PTV D95% (-2.75, -0.26) & (-4.29, -
2.27); CTV D100% (-2.41, -0.06) & (-0.95, 0.31); rectum V65% 
(-2.30, -0.48) & (-6.09,-3.20); and bladder V65% (-0.86, 0.50) 
& (-1.02, 1.72). In these fractions, PTV V105% was higher 
than the planned value with both KIM gating (2.98-22.18%) 
and with no KIM correction (17.16-27.25%). It should be noted 
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that the KIM has a finite gating threshold and therefore, in 
the presence of motion, it will deviate from the planned 
treatment. 
 
Figure 1. (a) Planned, (b) delivered with KIM gating, and (c) 
simulated delivery without KIM gating correction isodose 
distributions for a fraction of patient 1. Dose levels >95% are 
shown. 
 
Conclusions: The initial results indicate that KIM gating 
improves the agreement between the planned and delivered 
treatments for prostate radiotherapy. A more accurate 
delivery with KIM can facilitate dose escalation and also 
potentially improve treatment outcomes. Future work will 
include investigation of more patients and fraction data, and 
statistical analysis.  
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Purpose/Objective: Kilovoltage Intrafraction Monitoring 
(KIM) is a new real-time IGRT system undergoing first-in-
world clinical use. With KIM, the kV imager is employed while 
the MV beam is on. Radio-opaque markers implanted into the 
target are detected in the kV images, and 2D-to-3D 
reconstruction is performed to compute the 3D target 
position in real-time. The 3D target position is displayed to 
the clinical team during treatment and is used to make 
guidance decisions. KIM has shown sub-millimetre accuracy 
from phantom experiments and retrospective prostate and 
liver cancer patient studies. However to date there have 
been no prospective patient results where KIM is employed in 
real-time to make guidance decisions. We report the 
accuracy measurements from the first prospective clinical 
trial of KIM for prostate cancer VMAT patients. 
Materials and Methods: Simultaneous intratreatment kV and 
MV images of the 52 fractions from the three prostate cancer 
patients treated with KIM real-time guidance to date were 
acquired. For each treatment fraction the KIM real-time 
measurements of the prostate implanted marker positions 
were compared to retrospectively measured kV-MV 
triangulated marker positions. The kV-MV triangulated 
positions were considered to be the ground truth. The mean 
and standard deviation of the measured position differences 
between KIM and kV-MV triangulation in the left-right (LR), 
superior-inferior (SI) and anterior-posterior (AP) directions 
were recorded and analysed. Due to the VMAT MLC 
modulation, the markers were not visible in all MV images, 
however at least one marker was visible in 6461 (of 47320 
total) images, with the number of images available for 
analysis in any one fraction ranging from 66 to 167. 
Results: The mean error of KIM in the LR, SI and AP directions 
was 0.17, 0.55, and -0.61 mm respectively, with standard 
deviations of 0.56, 0.29 and 0.48 mm respectively. The 
accuracy results for each fraction of each patient are shown 
in the figure. The accuracy and precision are both sub-
millimetre. The results across the fractions and patients are 
quite similar, indicating that further improvements to the 
accuracy could be performed to reduce the residual small 
systematic accuracy error. 
 
 
Conclusions: A new real-time tumour position monitoring 
system, Kilovoltage Intrafraction Monitoring (KIM), has been 
clinically implemented and demonstrated to have sub-
millimetre accuracy and precision in the results to date. As 
KIM is implemented on a standard linear accelerator with 
little modification, this accurate technology can potentially 
be widely used on existing cancer radiotherapy systems.  
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Purpose/Objective: Radiotherapy treatment for breast 
cancer increases the risk of major coronary events1, with 
dose received by the Left Anterior Descending (LAD) coronary 
artery an area of particular concern2. Deep inspiration 
breath-hold (DIBH) is demonstrated as an effective method to 
reduce cardiac doses during breast irradiation3. Following its 
implementation across our centres a reduction of mean heart 
dose was observed for left sided breast radiotherapy. This 
study will further investigate these changes in cardiac dose 
and explore LAD mean and maximum doses. 
Materials and Methods: This retrospective study investigated 
275 left-sided breast cancer patients treated with DIBH 
